BioSpace News Archive

Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that on August 30, 2022, the Canadian Agency for Drugs and Technologies in Health (CADTH) Canadian Drug Expert Committee (CDEC) recommended VABYSMO® (faricimab injection) for public reimbursement.

Bio-Techne Corporation announced its plan to request shareholder approval during its upcoming 2022 Annual Meeting of Shareholders for an increase in the total number of authorized shares of common stock through an amendment to the Company’s Articles of Incorporation to implement a four-for-one forward stock split in the form of a stock dividend.

Zimmer Biomet Holdings, Inc., a global medical technology leader, announced an exclusive, multi-year co-marketing agreement with Surgical Planning Associates, Inc. to commercialize HipInsight™, the first FDA-cleared mixed reality navigation system for total hip replacement.

Bausch + Lomb Corporation and Alfa Instruments s.r.l. announced that the companies have entered into an exclusive distribution agreement under which Bausch + Lomb will distribute and commercialize Alfa Instruments’ line of surgical intraocular dyes, Vitreocare, globally with the exception of Italy, where Alfa Instruments is based.

Kezar Life Sciences, Inc. announced that Christopher Kirk, PhD, Co-founder, President and Chief Scientific Officer, will participate in three upcoming investor conferences in September.

Hyloris Pharmaceuticals SA, a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, reported its condensed consolidated financial results for the six-month period ending 30 June 2022, along with a year-to-date business update and an outlook.

Photocure ASA, the Bladder Cancer Company, announced the appointment of Dr. Anders Neijber to the position of Chief Medical Officer, Global Medical Affairs and Clinical Development and R&D, effective September 1, 2022.

XNK Therapeutics AB announced the successful completion of the building phase of the company’s new GMP clean room facility.

Avacta Group plc announces that the first-in-human Phase I trial of AVA6000 Pro-doxorubicin will advance to the fourth dose cohort of patients following a positive review of the safety and tolerability data from the dosing of the third cohort.

Osivax announced upcoming oral presentations at the Universal Influenza Vaccines 2022 event held September 5-7 in Oxford, UK and the Options XI for the Control of Influenza conference, held September 26-29 in Belfast, UK.